SRS16-86

Modify Date: 2024-01-12 10:47:31

SRS16-86 Structure
SRS16-86 structure
Common Name SRS16-86
CAS Number 1793052-96-6 Molecular Weight 432.558
Density 1.3±0.1 g/cm3 Boiling Point 614.9±55.0 °C at 760 mmHg
Molecular Formula C26H32N4O2 Melting Point N/A
MSDS N/A Flash Point 325.7±31.5 °C

 Use of SRS16-86


SRS16-86 is a potent inhibitor of ferroptosis[1]. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research[2][3].

 Names

Name SRS16-86
Synonym More Synonyms

 SRS16-86 Biological Activity

Description SRS16-86 is a potent inhibitor of ferroptosis[1]. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research[2][3].
Related Catalog
In Vitro SRS16-86 (1 µM; 24 hours; in the presence or absence of erastin) inhibits ferroptosis in HT-1080 cells and NIH 3T3 cells[2].
In Vivo SRS16-86 (intraperitoneal injection; 2 mg/kg; 15 min before the onset of surgery) protects mice from functional acute renal failure and structural organ damage after ischemia–reperfusion injury (IRI)[2]. SRS16-86 (intraperitoneal injection; 2 mg/kg; 4 weeks) combination therapy with [Nec-1+SfA] is superior in the prevention of renal IRI compared with the double-combination therapy with [Nec-1+SfA]. Addition of 16-86 reduces plasma levels of serum urea and serum creatinine in IRI mice model[2]. SRS16-86 (intraperitoneal injection; 15 mg/kg; once a day; 7 days) enhances functional recovery after SCI, it decreases the levels of proinflammatory cytokines and the inflammatory adhesion factor in injured spinal cord in rats[3]. Animal Model: Renal IRI model Dosage: 2 mg/kg; 15 min before the onset of surgery Administration: Intraperitoneal injection; 2 mg/kg; 15 min before the onset of surgery Result: Was protective from renal IRI. Animal Model: Renal IRI model Dosage: 2 mg/kg Administration: Combination with Necrostatin-1/Sanglifehrin A; 2 mg/kg; 4 weeks Result: Further increased the protective effect of [Necrostatin-1/Sanglifehrin A] combination therapy in renal IRI model.
References

[1]. Sam Hofmans, et al. Novel Ferroptosis Inhibitors with Improved Potency and ADME Properties. J Med Chem. 2016 Mar 10;59(5):2041-53.

[2]. Andreas Linkermann, et al. Synchronized renal tubular cell death involves ferroptosis.Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16836-41.

[3]. Yan Zhang, et al. Ferroptosis inhibitor SRS 16-86 attenuates ferroptosis and promotes functional recovery in contusion spinal cord injury. Brain Res. 2019 Mar 1;1706:48-57.

 Chemical & Physical Properties

Density 1.3±0.1 g/cm3
Boiling Point 614.9±55.0 °C at 760 mmHg
Molecular Formula C26H32N4O2
Molecular Weight 432.558
Flash Point 325.7±31.5 °C
Exact Mass 432.252533
LogP 4.93
Vapour Pressure 0.0±1.8 mmHg at 25°C
Index of Refraction 1.656

 Synonyms

Benzoic acid, 3-[[(1Z)-5-pyrimidinylmethylene]amino]-4-(tricyclo[3.3.1.13,7]dec-1-ylamino)-, 1,1-dimethylethyl ester
2-Methyl-2-propanyl 4-[(3s,5s,7s)-adamantan-1-ylamino]-3-[(Z)-(5-pyrimidinylmethylene)amino]benzoate
SRS16-86
Top Suppliers:I want be here



Get all suppliers and price by the below link:

SRS16-86 suppliers


Price: ¥800/5 mg

Reference only. check more SRS16-86 price